Table 1. Patients and controls
Subjects HLA-DRB1 HLA-A, -B
Recent-onset diabetes (R)
   1 01-03 A2-, B8-
   2 04-13 A2–24, B27-
   3 07-13 A1–2, B12–44
   4 03-03 A1–24, B16–39
   5 03-16 A2–11, B7–55
   6 04-08 A3–24, B39–49
   7 04-08 A24–80, B44–51
   8 04-13 A3–26, B38–63
   9 03-16 A2-, B45–18
   10 03-04 A2-, B62–52
   11 03-03 A9–10, B8–14
   12 03-04 A2–3, B18–38
   13 03-04 A1–29, B51–53
   14 03-13 A2-, B8-
   15 03-04 A11–26, B18–49
   16 03-11 A2–30, B16–18
   17 04-16 A1–24, B8–44
   18 03-08 A3–24, B8–58
   19 03-04 A2–3, B8–18
Long-standing diabetes (L)
   1 03-04 A1–26, B18–49
   2 03-03 A1–24, B8–45
   3 04-13 A11–24, B50-62
   4 03-04 A1-, B8–44
   5 03-04 A2-, B35–62
   6 03-03 A3–31, B8–51
   7 03-04 A1–24, B8–49
   8 03-04 A1–9, B8–21
   9 03-04 A1–3, B8–49
   10 04-04 A2-, B39–62
   11 01-01 A2–24, B7–35
   12 03-04 A1-, B8–38
   13 03-04 A2–29, B7–35
Controls (C)
   1* 03-04 A2-, B45–18
   2* nd A2–10, B12–14
   3* 03-14 A1–11, B8–55
   4* 03-15 A2-, B35–44
   5* , 01-11 A1–2, B7-
   6* , 03-07 A16–19, B8–44
   7* , 03-13 A2-, B38–45
   8 nd A1–23, B37–61
   9 nd A24-, B7–35
   10 nd A1–3, B8–27
   11 nd A2–29, B7–44
   12 nd A2–3, B38–51
   13 nd A24–28, B7–8
   14 nd A2-, B27–44
   15 nd A1–30, B8–13
   16 nd A1–32, B8–13
   17 nd A2–31, B35–60
   18 nd A2–3, B7–12
   19 nd A2-, B8-
  • nd, not done.

  • * Type 2 diabetes

  • Insulin-treated